# A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG

> **NCT05123534** · PHASE2 · SUSPENDED · sponsor: **SonALAsense, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma

## Interventions

- **COMBINATION_PRODUCT:** SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)

## Key facts

- **NCT ID:** NCT05123534
- **Lead sponsor:** SonALAsense, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-08-12
- **Primary completion:** 2024-07-30
- **Final completion:** 2024-10-30
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** The study is suspended due to lack of funding but not due to safety concerns.
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05123534

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05123534, "A Phase 2 Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05123534. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*